uniQure investor relations material

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Through its adeno-associated virus (AAV) based gene therapy platform, the company develops proprietary power gene therapies that can be used to treat diseases with a high unmet need. Its lead program is focused on Hemophilia B and Huntington's disease.